Sarcoidosis- a systemic disease. What is new?

Czech version

Authors: M. Vašáková; M. Šterclová; J. Anton
Authors‘ workplace: Primářka: MUDr. Martina Vašáková, Ph. D. ; Fakultní Thomayerova nemocnice s poliklinikou, Praha ; Přednostka: MUDr. Václava Bártů ; Pneumologická klinika 1. LF UK
Published in: Prakt. Lék. 2008; 88(4): 208-212
Category: Various Specialization

Overview

Sarcoidosis, although normally regarded as a pulmonary disease, is, in its nature, a classical systemic disease. From an ethiopathogenetic point of view, the diseases is characterized by non-caseated granuloma formation, which can involve almost all of the organs in the human body, some of them with clinical manifestation and some asymptomatically. In addition to organ involvement the disease also has immunopathologic and metabolic manifestations. Chronic fatigue is considered to be one of the most difficult of the sarcoidosis symptoms to treat. In general, the acute disease with prominent intrathoracic involvement and often with spontaneous regression is prognostically the most favourable form of sarcoidosis. Chronic forms of the disease with prominent extrapulmonary manifestation, usually involving the heart or central nervous system, have much worse prognosis and can be fatal.

The treatment modalities of sarcoidosis comprise mainly of corticosteroids, alternatively antimalaric drugs and immunosuppresives. The biological treatment, targeted against TNF-alpha mediated immunopathologic response, has been recently tried in some cases of the disease.

Key words:
sarcoidosis, granulomas, multiorgan involvement, prognosis, treatment.

Sources

1. Akira, M. Kozuka, T. Inoue, Y. et al. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 2005, 127, 1, p. 185-191.

2. American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders. Statement on sarcoidosis. Am. J. Respir. Crit. Care Med. 1999, 160, p. 736-755.

3. Bradley, D., Baughmann, RP. Raymond, L. et al. Ocular manifesation of sarcoidosis. In Extrapulmonary sarcoidosis. Seminars in Respiratory and Critical Care Medicine 2002, 23, 6, p. 543-548.

4. Deng, J.C., Baughmann, R.P., Lynch, J.P. Cardiac involvement in sarcoidosis. In Extrapulmonary sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 6, p. 513-527.

5. Epstein, W. Cutaneous Sarcoidosis. In Extrapulmonary sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 6, p. 571-577.

6. Grutters, J.C., van den Bosch, M.M. Corticosteroid treatment in sacoidosis. Eur. Respir. J. 2006, 2, p. 627-636.

7. Iannuzzi, M.C., Rybicki, B.A., Teirstein, A.S. Sarcoidosis. N. Engl. J. Med. 2007, 357(21), p. 2153-2165.

8. Judson, M.A. Hepatic, splenic, and gastrointestinal involvement with sarcoidosis. In Extrapulmonary sarcoidosis. Seminars in Respiratory and Critical Care Medicine 2002, 23, 6, p. 529-541.

9. Kriegova, E. Melle, C. Kolek, V. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 2006, 173, p. 1145- 1154.

10. Martin, W.J., Iannuzzi, M.C., Gail, D.B. et al. Future directions in sarcoidosis research. Summary of an NHLBI Working Group. Am. J. Respir. Crit. Care Med. 2004, 170, p. 567-571.

11. Polák, J., Vašáková, M., Bártů, V. a kol. Význam vysoce rozlišující výpočetní tomografie/HRCT/ při sledování nemocných s plicní sarkoidózou. Stud. Pneumol. Phtiseol. 1994, 54, 6, s. 424-433.

12. Proceedings of XII. World Congress Sarcoidosis 1991. Sarcoidosis, 1992, 9, (Suppl 1), p. 34.

13. Rybicki, B.A., Ianuzzi, M.C., Frederick, M.M. et al. Familial aggregation of sarcoidosis: A Case-Control Etiologic Study of Sarcoidosis (ACCESS). Am. J. Respir. Crit. Care Med. 2001, 164, p. 2085-2091.

14. Saleh, S., Ghodsian, S., Yakimova, V. et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respiratory Medicine 2006, 100, p. 2053-2059.

15. Sharma, O.P., Vučinič, V. Sarcoidosis of the thyroid and kidneys and calcium metabolism. In Extrapulmonary sarcoidosis. Seminars in Respiratory and Critical Care Medicine 2002, 23, 6, p. 579-588.

16. Teirstein, A. Neuromuscular sarcoidosis. In Extrapulmonary sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 6, p. 505-512.

17. Teirstein, A.S., Machac, J., Almeida, O. et al. Results of 188 whole-body fluorodeoxyglukose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007, 132, 6, p. 1949-1953.

18. Ziegenhagen, M.W., Rothe, M.E., Schlaak, M. et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur. Respir. J. 2003, 21, p. 407-413.

19. Zisman, D.A., Shor, A.F., Lynch, J.P. Sarcoidosis involving the musculosceletal system. In Extrapulmonary sarcoidosis. Seminars in Respiratory and Critical Care Medicine 2002, 23, 6, p. 555-570.